New concepts and paradigms in cardiovascular medicine: The noninvasive management of coronary artery disease

American Journal of Medicine

Volumn 104, Issue 6 A, 1998, Pages 2S-17S

  Gould, K Lance ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HUMAN; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; LOW FAT DIET; MORTALITY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; WEIGHT REDUCTION;

EID: 0031859379     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00140-5     Document Type: Review

References (183)

1. Gould KL. Coronary Artery Stenosis and Reversing Heart Disease. 2nd ed. New York: Lippincott Raven Press, 1998. In press.
2. Gould KL. Reversal of coronary atherosclerosis: clinical promise as the basis for the non-invasive management of coronary artery disease. Circulation. 1994;90:1558-1571.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
4. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
5. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basis mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
6. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary artery disease. Circulation. 1993;87:1781-1791.
7. Navab M, Fogelman AM, Berliner JA, et al. Pathogenesis of atherosclerosis. Am J Cardiol. 1995;76:18C-23C.
8. Farb A, Tang AL, Burke AP, et al. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995;92: 1701-1709.
9. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
10. Shah PK, Falk E, Badimon JJ, et al. Human monocytederived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565-1569.
11. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;92:1084-1088.
12. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-318.
13. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944.
14. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 1992;71:850-858.
15. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. Circulation. 1996:93: 1354-1363.
16. Constantinides P. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;92:1083.
17. Mann J, Davies MJ. Vulnerable plaque: relation of characteristics to degree of stenosis in human coronary arteries. Circulation. 1996;94:928-931.
18. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation. 1990;81:428-436.
19. 201TI myocardial scintigraphy in asymptomatic young men. Circulation. 1993;87: 165-172.
20. Mangano DT, London MJ, Tubau JF, et al. Dipyridamole thallium 201-scintigraphy as a perioperative screening test, a reexamination of its predictive potential. Circulation. 1991;84:493-502.
21. Koistinen MJ, Huikuri HV, Pirttiaho H, Linnaluoto MK, Takkunen JT. Evaluation of exercise electrocardiography and thallium tomographic imaging in detecting asymptomatic coronary artery disease in diabetic patients. Br Heart J. 1990;63:7-11.
22. Krone RJ, Gregory JJ, Freedland KE, et al. Limited usefulness of exercise testing and thallium scintigraphy in evaluation of ambulatory patients several months after recovery from an acute coronary event: implications for management of stable coronary heart disease. J Am Coll Cardiol. 1994;24:1274-1281.
23. Bodenheimer MM. Risk stratification in coronary disease: a contrary viewpoint. Ann Intern Med. 1992;116:927-936.
24. Bogaty P, Dagenais GR, Cantin B, Alain P, Rouleau JR. Prognosis in patients with strongly positive exercise electrocardiogram. Am J Cardiol. 1989;64:1284-1288.
25. Smith SC. Risk-reduction therapy: the challenge to change. Circulation. 1996;93:2205-2211.
26. Seiler C, Kirkeeide RL, Gould KL. Basic structure-function relations of the epicardial coronary vascular tree - the basis of quantitative coronary arteriography for diffuse coronary artery disease. Circulation. 1992;85:1987-2003.
27. Seiler C, Kirkeeide RL, Gould KL. Measurement from arteriograms of regional myocardial bed size distal to any point in the coronary arterial tree for assessing anatomic area at risk. J Am Coll Cardiol. 1993;21:783-797.
28. Hodgson JM, Reddy KG, Suneja R, et al. Intracoronary ultrasound imaging: correlation of plaque morphology with angiography, clinical syndrome and procedural results in patients undergoing coronary angioplasty. J Am Coll Cardiol. 1993;21:35-44.
29. Porter TR, Sears T, Xie F, et al. Intravascular ultrasound study of angiographically mildly diseased coronary arteries. J Am Coll Cardiol. 1993;22:1858-1865.
30. Yamagishi M, Miyatake K, Tamai J, et al. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. J Am Coll Cardiol. 1994;23: 352-357.
31. Dupouy P, Larrazet F, Ghalid A, Rande JLD, Geschwind HJ. Is intravascular ultrasound a new standard for coronary artery imaging? J Intervent Cardiol. 1993;6:321-330.
32. St. Goar FG, Pinto FJ, Alderman EL, et al. Detection of coronary atherosclerosis in young adult hearts using intravascular ultrasound. Circulation. 1992;86:756-763.
33. St. Goar FG, Pinto FJ, Alderman EL, et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: an in vivo comparison with quantitative angiography. J Am Coll Cardiol. 1991;18:952-958.
34. Mintz GS, Painter JA, Pichard AD, et al. Atherosclerosis in angiographically normal coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol. 1995;25:1479-1485.
35. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation. 1995;92:2333-2342.
36. Nishioka T, Luo H, Eigler NL, et al. Contribution of inadequate compensatory enlargement to development of human coronary artery stenosis: an in vivo intravascular ultrasound study. J Am Coll Cardiol. 1996;27:1571-1576.
37. Mintz GS, Popma JJ, Pichard AD, et al. Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions. Circulation. 1996;93: 924-931.
38. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43.
39. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
40. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 1989;83:1946-1952.
41. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
42. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercised-induced myocardial ischemia. Circulation. 1995;91:2345-2352.
43. Quyyumi AA, Dakak N, Andrews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 1995;92:320-326.
44. Schächinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo. Circulation. 1995;92:2087-2094.
45. Penny WF, Rockman H, Long J, et al. Heterogeneity of vasomotor response to acetylcholine along the human coronary artery. J Am Coll Cardiol. 1995;25:1046-1055.
46. Kuo L, Davis MJ, Chilian WM. Longitudinal gradients for endothelium-dependent and -independent vascular responses in the coronary microcirculation. Circulation. 1995;92:518-525.
47. Uren NG, Marraccini P, Gistri R, deSilva R, Camici PG. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol. 1993;22:650-658.
48. Reddy KG, Nair RV, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 1994;23:833-843.
49. El-Tamini H, Mansour M, Wargovich TJ, et al. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Circulation. 1994;89:45-51.
50. Hodgson JM, Marshall JJ. Direct vasoconstriction and endothelium-dependent vasodilation: mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation. 1989;79:1043-1051.
51. Harrison DG. Endothelial dysfunction in the coronary microcirculation: a new clinical entity or an experimental finding? J Clin Invest. 1993;91:1-2.
52. Chilian WM, Dellsperger KC, Layne SM, et al. Effects of atherosclerosis on the coronary microcirculation. Am J Physiol. 1990;258:H529-H539.
53. Selke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990;81:1586-1593.
54. Kuo L, Davis MJ, Cannon S, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res. 1992;70:465-476.
55. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991;84: 1984-1992.
56. Armstrong ML, Heistad DD, Marcus ML, Piegors DJ, Abboud FM. Hemodynamic sequelae of regression of experimental atherosclerosis. J Clin Invest. 1983:71:104-113.
57. Tomita T, Ezaki M, Miwa M, Nakamura K, Inoue Y. Rapid and reversible inhibition by low density lipoprotein of the endothelium-dependent relaxation to hemostatic substances in porcine coronary arteries. Circ Res. 1990;66: 18-27.
58. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80: 1801-1811.
59. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol. 1994;23:844-850.
60. Benzuly KH, Padgett RC, Kaul S, et al. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818.
61. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol lowering and anti-oxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
62. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol. 1996;27:658-663.
63. Shircore AM, Mack WJ, Selzer RH, et al. Compensatory vascular changes of remote coronary segments in response to lesion progression as observed by sequential angiography from a controlled clinical trial. Circulation. 1995;92:2411-2418.
64. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;94:258-265.
65. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation. 1996;94:266-272.
66. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 1997;96:3266-3268.
67. Brown GB, Albers JJ, Fisher LD, et al. Niacin or lovastatin combined with colestipol regresses coronary atherosclerosis and prevents clinical events in men with elevated apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
68. Ornish DM, Scherwitz LW, Brown SE, et al. Can lifestyle changes reverse atherosclerosis? Lancet. 1990;336:129-133.
69. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990; 264:3007-3012.
70. Gould KL, Ornish D, Kirkeeide R, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. Am J Cardiol. 1992;69:845-853.
71. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
72. Schuler G, Hambrecht R, Schlierf G, et al. Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. J Am Coll Cardiol. 1992;19:34-42.
73. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation. 1992;86:1-11.
74. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
75. Singh RB, Rastogi SS, Verna R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992;304:1015-1029.
76. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
77. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA. 1990;264:3013-3017.
78. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease, the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
79. National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
80. Blankenhorn DH. Angiographic trials testing the efficacy of cholesterol lowering in reducing progression or inducing regression of coronary atherosclerosis. Coron Artery Dis. 1991;2:875-879.
81. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases in size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation. 1994;89:1530-1538.
82. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
83. Gould K, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA. 1995;274:894-901.
84. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
85. Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA. 1995;273:1113-1117.
86. Stewart BF, Brown BG, Zhao X-Q, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low-density lipoprotein cholesterol. J Am Coll Cardiol. 1994;23:899-906.
87. Buchwald H, Campos CT, Boen JR, Nguyen PA, Williams SE. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol. 1995; 26:351-357.
88. Shepherd J, Cobbe SM, Ford I, et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
89. Sacks FM, Pffeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
90. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation. 1994;89: 959-968.
91. Blankenhorn DH, Azren S, Kramsch DM, et al, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy. Ann Intern Med. 1993;119:969-976.
92. MAAS Investigators. Effects of simvastatin on coronary atheroma. Lancet. 1994;344:633-638.
93. Zhao XQ, Grown BG, Hillger L, et al. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation. 1993;88:2744-2753.
94. Denke MA, Winker MA. Cholesterol and coronary heart disease in older adults. No easy answers. JAMA. 1995; 274:575-577.
95. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
96. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II coronary intervention study. Circulation. 1984;69:313-324.
97. Furberg CD, Pitt B, Byington RP, Park J-S, McGovern ME, for the PLAC I and PLAC II investigators. Reduction in coronary events during treatment with pravastatin. Am J Cardiol. 1995;76:60C-63C.
98. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345: 1274-1275.
99. Salonen R, Nvyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS). Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76:34C-39C.
100. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progress in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
101. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
102. De Groot E, Jukema W, van Boven AJ, et al, on behalf of the REGRESS study group. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol. 1995;76:40C-46C.
103. van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 1996;94:1503-1505.
104. de Divitiis M, Rubba P, DiSomma S, et al. Effects of short term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol. 1996;78:763-768.
105. Wysowski OK, Kennedy DL, Gross TP. Prescribed use of cholesterol lowering drugs in the United States, 1978 through 1988. JAMA. 1990;263:2185-2188.
106. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol. 1995;76:570-573.
107. LaRosa JC, Cleeman JI. Cholesterol lowering as a treatment for established coronary heart disease. Circulation. 1992;85:1229-1234.
108. Cohen MV, Byrne M-J, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-1304.
109. Marceline JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
110. Byington RP, Jukema W, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425.
111. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Circulation. 1996;93:1796-1802.
112. Waters D, Higginson L, Gladstone P, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. Circulation. 1995;92:2404-2410.
113. Ericsson CG, Hamsten A, Nisson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
114. Feher MD, Foxton J, Banks D, Lant AF, Wray LR. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. ACC Current J Review. 1995;74: 14-17.
115. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172-3177.
116. Eichstädt HW, Eskötter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 1995;76:122A-125A.
117. Herd JA, Ballantyne CM, Farmer JA, et al. Beneficial effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations: the Lipoprotein and Coronary Atherosclerosis Study (LCAS). Am J Cardiol. 1997;80:278-286.
118. Patsch JR, Miesenböck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
119. Salomaa V, Rasi V, Pekkanen J, et al. The effects of saturated fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity. Atherosclerosis. 1993; 103:1-11.
120. Karpe F, Steiner G, Uffelman K, Olivecrona T, Amsten A. Postprandial lipoproteins and progress of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
121. Uiterwaal CSPM, Grobbee DE, Witteman JCM, et al. Post-prandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med. 1994;121:576-583.
122. Tornvall P, Båvenholm P, Landou C, deFaire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation. 1993;88:2180-2189.
123. Drexel H, Amann FW, Beran J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 1994;90:2230-2235.
124. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
125. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.
126. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation. 1992;86:1165-1170.
127. Burchfiel CM, Laws A, Benfante R, et al. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation. 1995;92:1430-1436.
128. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539-544.
129. Paunio M, Heinonen OP, Virtamo J, et al. HDL cholesterol and mortality in Finnish men with special reference to alcohol intake. Circulation. 1994;90:2902-2918.
130. Atger V, Giral P, Simon A, et al. High-density lipoprotein subfractions as markers of early atherosclerosis. Am J Cardiol. 1995;75:127-131.
131. Lien WP, Lai LP, Shyu KG, et al. Low-serum, high-density lipoprotein cholesterol concentration is an important coronary risk factor in Chinese patients with low serum levels of total cholesterol and triglyceride. Am J Cardiol. 1996; 77:1112-1115.
132. Frost PH, Davis BR, Burlando AJ, et al. Coronary heart disease risk factors in men and women aged 60 years and older. Circulation. 1996;94:26-34.
133. Superko HR, Orr JR, Krauss RM. Reduction of small, dense LDL by gemfibrozil in LDL subclass pattern B. (Abstr.) Circulation. 1995;92:1-250.
134. Marx HJ, Nafziger AN, Jenkins P, et al. Does gemfibrozil prevent coronary disease by reduction of postprandial triglyceride-rich lipoproteins? Differences between triglyceride/HDL subgroups. (Abstr.) Circulation. 1995;92:1-250.
135. O'Keefe JD Jr, Harris WS, Nelson J, Windsor SL Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995;76:480-484.
136. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 1995;26:1615-1622.
137. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2:757-761.
138. Rimm EB, Giovannucci E, et al. Increased fiber intake in men was associated with reduced MI. JAMA. 1996;275: 447-451.
139. Rimm EB, Ascherio A, Giovannucci E, et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA. 1996;275:447-451.
140. Wolfe BM, Giovannetti PM. Short-term effects of substituting protein for carbohydrate in the diets of moderately hypercholesterolemic human subjects. Metabolism. 1991; 40:338-343.
141. Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-1459.
142. Quinn TG, Alderman EL, McMillan A, Haskel W, for the SCRIP Investigators. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). J Am Coll Cardiol. 1994;24:900-908.
143. Yusuf S, Anand S. Cost of prevention. The case of lipid lowering. Circulation. 1996;93:1774-1776.
144. Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med. 1990;150:2169-2172.
145. Kuller LH, Shaten J, Neaton JD, Cutler JA. Traumatic deaths in the Multiple Risk Factor Intervention Trial. Circulation. 1992;86(suppl 1):1-64.
146. Weidner G, Connor SL, Hollis JF, Connor WE. Improvements in hostility and depression in relation to dietary change and cholesterol lowering. The Family Heart Study. Ann Intern Med. 1992;117:820-823.
147. National Task Force on the Prevention and Treatment of Obesity. Very low-calorie diets. JAMA. 1993;270:967-974.
148. Vartiainen E, Puska P, Pekkanen J, et al. Serum cholesterol concentration and mortality from accidents, suicide, and other violent causes. BMJ. 1994;309:445-447.
149. Iribarren C, Reed DM, Burchfiel CM, Dwyer JH. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA. 1995;273:1926-1932.
150. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation. 1995;92:2396-2403.
151. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physiochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73:1590-1605.
152. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
153. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997;79:350-354.
154. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 1997;278:1682-1686.
155. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation. 1997;95:76-82.
156. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
157. Czernin J, Barnard J, Sun KT, et al. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation. 1995;92: 197-204.
158. Vogel R. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol. 1997;20:426-432.
159. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328.
160. Treasure CB, Klein L, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
161. McPherson DD, Sirna SJ, Hiratzka LF, et al. Coronary arterial remodeling studied by high-frequency epicardial echocardiography: an early compensatory mechanism in patients with obstructive coronary atherosclerosis. J Am Coll Cardiol. 1991;17:79-86.
162. Fleming RM, Kirkeeide RL, Smalling RW, Gould KL, Stuart Y. Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography. J Am Coll Cardiol. 1991;18:945-951.
163. Rensing BJ, Hermans WRM, Beatt KJ, et al. Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990;66:1039-1044.
164. Tuzcu EM, Hobbs RE, Rincon G, et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation. 1995;91:1706-1713.
165. Tuzcu EM, De Franco AC, Goormastic M, et al. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol. 1996;27:837-846.
166. Hausmann D, Johnson JA, Sudhir K, et al. Angiographically silent atherosclerosis detected in intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. J Am Coll Cardiol. 1996;27:1562-1570.
167. Nakagawa Y, Gould KL Longitudinal base to apex perfusion gradients by dipyridamole Positron Emission Tomography indicate diffuse coronary atherosclerosis. (Abstr.) Circulation. 1996;94:1-602.
168. Armstrong ML, Heistad DD, Marcus ML, Megan MB, Piegors DJ. Structural and hemodynamic responses of peripheral arteries of macaque monkeys to atherogenic diet. Arteriosclerosis. 1985;5:336-346.
169. Gould KL, Goldstein RA, Mullani N. Economic analysis of clinical positron emission tomography of the heart with rubidium-82. J Nucl Med. 1989;30:707-717.
170. Merhige ME, Houston T, Shellon V, et al. PET myocardial perfusion imaging reduces the cost of coronary disease management. (Abstr.) Circulation. 1997;96:8.
171. Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Circulation. 1994; 90:2687-2694.
172. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693-1700.
173. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of coronary artery bypass surgery for stable angina. Circulation. 1992;86:121-130.
174. Scott SM, Deupree RH, Sharma GVRK, Luchi RJ. VA study of unstable angina. 10-year results show duration of surgical advantage for patients with impaired ejection fraction. Circulation. 1994;90:11-120-11-123.
175. CASS Principal Investigators. Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery by-pass surgery. Circulation. 1983;68:939-950.
176. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation. 1995;91:2335-2344.
177. Hueb WA, Bellotti G, deOliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a protective randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26:1600-1605.
178. Cox JL, Petrie J, Pollak PT, Johnstone DE. Managed delay for coronary artery bypass graft surgery: the experience at one Canadian center. J Am Coll Cardiol. 1996;27:1365-1373.
179. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-570.
180. RITA-2 Participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet. 1997;350:461-468.
181. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of angioplasty. Circulation. 1994;89:2015-2025.
182. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation. 1997;95:2037-2043.
183. Gould KL. Heal Your Heart: How You Can Prevent or Reverse Heart Disease. New Brunswick, NJ: Rutgers University Press, 1998. In press.